Stockreport

Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy

Capricor Therapeutics, Inc.  (CAPR) 
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF ­ -CAP-1002 Aims to Mitigate Severe Inflammatory Response Associated with COVID-19- -Expanded Access Protocol Submitted to FDA- LOS ANGELES, April 03, 2020 (GLOBE N [Read more]